BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of $0.96, $0.61 better than the analyst estimate of $0.35. Revenue for the quarter came in at $712 million versus the consensus estimate of $662.05 million.

GUIDANCE:

BioMarin Pharma sees FY2024 EPS of $3.10-$3.25, versus the consensus of $2.87. BioMarin Pharma sees FY2024 revenue of $2.75-2.82 billion, versus the consensus of $2.74 billion.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.